Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 300 mg - capsule, hard - excipient ingredients: maize starch; lactose; purified talc; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 400 mg - capsule, hard - excipient ingredients: maize starch; lactose; purified talc; titanium dioxide; purified water; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - gabapentin, quantity: 100 mg - capsule, hard - excipient ingredients: lactose; purified talc; maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - pharmagabapentin is indicated for the treatment of,? partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,? neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - ibuprofen, quantity: 400 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; lactose monohydrate; hypromellose; macrogol 6000; sodium lauryl sulfate; microcrystalline cellulose; purified water; purified talc; povidone; stearic acid; titanium dioxide - for the temporary relief of pain and/or inflammation associated with headache, migraine headache, tension headache, neuralgia, muscular aches & pains, back pain, fibrositis, arthritis, oesteoarthritis, rheumatic pain, tennis elbow. toothache & dental pain, period pain, sinus pain, sore throat and cold & flu. reduces fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefuroxime axetil, quantity: 300.715 mg - tablet, film coated - excipient ingredients: crospovidone; croscarmellose sodium; calcium carbonate; calcium stearate; purified water; colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; titanium dioxide; hypromellose; propylene glycol; brilliant blue fcf aluminium lake - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria: acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. acute exacerbations of chronic bronchitis, or acute bronchitis. skin and skin structure infections for example, furunculosis, pyoderma and impetigo. acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefuroxime axetil, quantity: 601.43 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; calcium stearate; microcrystalline cellulose; sodium lauryl sulfate; purified water; calcium carbonate; croscarmellose sodium; titanium dioxide; hypromellose; propylene glycol; brilliant blue fcf aluminium lake - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria: acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. acute exacerbations of chronic bronchitis, or acute bronchitis. skin and skin structure infections for example, furunculosis, pyoderma and impetigo. acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - oxycodone hydrochloride, quantity: 5 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; silicon dioxide; lactose monohydrate; maize starch; stearic acid - mayne pharma oxycodone ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.69 mg - capsule, enteric - excipient ingredients: polysorbate 20; triethyl citrate; mannitol; diacetylated monoglycerides; purified water; sodium benzoate; polysorbate 80; titanium dioxide; sucrose; propylene glycol; sorbic acid; maize starch; octoxinol; dimeticone 350; propyl hydroxybenzoate; purified talc; stearoyl macrogolglycerides; gelatin; hypromellose; methyl hydroxybenzoate; iron oxide yellow; methacrylic acid - ethyl acrylate copolymer (1:1); ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - pharmacy choice esomeprazole heartburn relief is indicated for the symptomatic relief of frequent heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux disease (gord).

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - dexmedetomidine hydrochloride 0.1182 mg/ml equivalent to dexmedetomidine 0.1mg/ml - concentrate for injection - active: dexmedetomidine hydrochloride 0.1182 mg/ml equivalent to dexmedetomidine 0.1mg/ml excipient: sodium chloride water for injection - for sedation of initially intubated patients during treatment in an intensive care setting. the use of dexmedetomidine hydrochloride ever pharma by continuous intubation in these patents should not exceed 24 hours. for sedation of non-intubated patients prior to and/or during surgical and other procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - terbinafine hydrochloride, quantity: 10 mg - cream - excipient ingredients: benzyl alcohol; polysorbate 60; purified water; sorbitan monostearate; sodium hydroxide; cetyl alcohol; stearyl alcohol; isopropyl myristate; cetyl palmitate - treatment of ringworm (tinea corporis, tinea cruris and tinea pedis) caused by dermatophytes such as trichophyton (e.g. t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis, and epidermophyton floccosum.,cutaneous candidiasis